[1]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30. https://doi.org/10.3322/caac.21442
|
[2]
|
Liu, G.X., Liu, P. and Tang, C. (2012) Relationship between NUSAP1 Expression and Lymph Node Metastasis in Bladder Urothelial Carcinoma. Western Medicine, 34, 240-244.
|
[3]
|
Dobruch, J. and Oszczudłowski, M. (2021) Bladder Cancer: Current Challenges and Future Directions. Medicina, 57, Article 749. https://doi.org/10.3390/medicina57080749
|
[4]
|
Patel, V.G., Oh, W.K. and Galsky, M.D. (2020) Treatment of Muscle‐Invasive and Advanced Bladder Cancer in 2020. CA: A Cancer Journal for Clinicians, 70, 404-423. https://doi.org/10.3322/caac.21631
|
[5]
|
Langenstroer, P., Zacharias, A., Almagro, U. and Dewire, D. (1996) Annular Constriction of the Rectum Secondary to Transitional Cell Carcinoma of the Bladder. Urology, 47, 442-444. https://doi.org/10.1016/s0090-4295(99)80471-3
|
[6]
|
Saitoh, H., Hida, M., Wakabayashi, T., Iida, T. and Satoh, T. (1982) Metastasis of Urothelial Tumors of the Bladder: Correlation between Sites and Number of Organs Involved. The Tokai Journal of Experimental and Clinical Medicine, 7, 517-526.
|
[7]
|
Takeuchi, H., Tokuyama, N., Kuroda, I. and Aoyagi, T. (2016) Annular Rectal Constriction Caused by Infiltrating Bladder Cancer: A Case Report. Molecular and Clinical Oncology, 5, 842-844. https://doi.org/10.3892/mco.2016.1047
|
[8]
|
Stillwell, T.J., Rife, C.C. and Lieber, M.M. (1989) Bladder Carcinoma Presenting with Rectal Obstruction. Urology, 34, 238-240. https://doi.org/10.1016/0090-4295(89)90315-4
|
[9]
|
Ito, Y., Nishimoto, K., Ogata, K. and Fujioka, T. (2008) [Annular Constriction of the Rectum Secondary to Urothelial Carcinoma of the Bladder]. Hinyokika Kiyo, 54, 553-555.
|
[10]
|
Kobayashi, S., Kato, H., Iijima, K., Kinebuchi, Y., Igawa, Y. and Nishizawa, O. (2006) Annular Rectal Constriction Due to Infiltration by Bladder Cancer. Hinyokika Kiyo, 52, 569-572.
|
[11]
|
Cathomas, R., Lorch, A., Bruins, H.M., Compérat, E.M., Cowan, N.C., Efstathiou, J.A., et al. (2022) The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. European Urology, 81, 95-103. https://doi.org/10.1016/j.eururo.2021.09.026
|
[12]
|
Moch, H., Amin, M.B., Berney, D.M., Compérat, E.M., Gill, A.J., Hartmann, A., et al. (2022) The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. European Urology, 82, 458-468. https://doi.org/10.1016/j.eururo.2022.06.016
|
[13]
|
Christensen, E., Birkenkamp-Demtröder, K., Nordentoft, I., Høyer, S., van der Keur, K., van Kessel, K., et al. (2017) Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. European Urology, 71, 961-969. https://doi.org/10.1016/j.eururo.2016.12.016
|
[14]
|
Korkes, F., Fernandes, E., Gushiken, F.A., Glina, F.P.A., Baccaglini, W., Timóteo, F., et al. (2022) Bricker Ileal Conduit Vs. Cutaneous Ureterostomy after Radical Cystectomy for Bladder Cancer: A Systematic Review. International braz j urol, 48, 18-30. https://doi.org/10.1590/s1677-5538.ibju.2020.0892
|
[15]
|
Gakis, G., Efstathiou, J., Lerner, S.P., Cookson, M.S., Keegan, K.A., Guru, K.A., et al. (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder. European Urology, 63, 45-57. https://doi.org/10.1016/j.eururo.2012.08.009
|
[16]
|
Powles, T., Park, S.H., Voog, E., Caserta, C., Valderrama, B.P., Gurney, H., et al. (2020) Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 383, 1218-1230. https://doi.org/10.1056/nejmoa2002788
|
[17]
|
Loriot, Y., Necchi, A., Park, S.H., Garcia-Donas, J., Huddart, R., Burgess, E., et al. (2019) Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 381, 338-348. https://doi.org/10.1056/nejmoa1817323
|
[18]
|
Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J., Fong, L., et al. (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 376, 1015-1026. https://doi.org/10.1056/nejmoa1613683
|
[19]
|
Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S.Y., et al. (2021) KEYNOTE-361 Investigators. Pembrolizumab Alone or Combined with Chemotherapy versus Chemotherapy as First-Line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 931-945.
|
[20]
|
Fry, D.E., Amin, M. and Harbrecht, P.J. (1979) Rectal Obstruction Secondary to Carcinoma of the Prostate. Annals of Surgery, 189, 488-492.
|
[21]
|
Miettinen, M., McCue, P.A., Sarlomo-Rikala, M., Rys, J., Czapiewski, P., Wazny, K., et al. (2014) GATA3: A Multi-Specific but Potentially Useful Marker in Surgical Pathology: A Systematic Analysis of 2500 Epithelial and Nonepithelial Tumors. American Journal of Surgical Pathology, 38, 13-22. https://doi.org/10.1097/pas.0b013e3182a0218f
|